Combined conjugated esterified estrogen plus methyltestosterone supplementation and risk of breast cancer in postmenopausal women

Geoffrey C. Kabat, Victor Kamensky, Moonseong Heo, Jennifer W Bea, Lifang Hou, Dorothy S. Lane, Simin Liu, Lihong Qi, Michael S. Simon, Jean Wactawski-Wende, Thomas E. Rohan

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives Testosterone supplementation is being prescribed increasingly to treat symptoms of hormone deficiency in pre- and postmenopausal women; however, studies of the association of testosterone therapy, alone or in combination with estrogen, with risk of breast cancer are limited. The current study assessed the association of combination conjugated esterified estrogen and methyltestosterone (CEE + MT) use and breast cancer risk in postmenopausal women in the Women's Health Initiative (WHI). Study design At Year 3 of follow-up, women in the WHI observational study (N = 71,964) provided information on CEE + MT use in the past two years, duration of use, and the brand name of the product. In addition, in each of years 4-8, women were asked whether they had used CEE + MT in the previous year. After 10 years of follow-up, 2832 incident breast cancer cases were identified. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI) for the association of CEE + MT use (irrespective of use of other hormones) and of exclusive CEE + MT use in relation to breast cancer risk. Results Neither CEE + MT use nor exclusive use of CEE + MT was associated with risk: multivariable-adjusted HR 1.06, 95% CI 0.82-1.36 and HR 1.22, 95% CI 0.78-1.92, respectively. Among women with a natural menopause, the HR for exclusive use was 1.32 (95% CI 0.68-2.55). There was no indication of an association when repeated measures of CEE + MT use were included in a time-dependent covariates analysis. Conclusion The present study, the largest prospective study to date, did not show a significant association of CEE + MT supplementation and risk of breast cancer.

Original languageEnglish (US)
Pages (from-to)70-76
Number of pages7
JournalMaturitas
Volume79
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Methyltestosterone
Conjugated (USP) Estrogens
Hazards
Estrogens
Breast Neoplasms
Confidence Intervals
Women's Health
Testosterone
Hormones
Menopause
Proportional Hazards Models
Names
Observational Studies
Prospective Studies

Keywords

  • Androgens
  • Breast cancer
  • Conjugated esterified estrogen plus methyltestosterone supplementation
  • Postmenopausal women

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Combined conjugated esterified estrogen plus methyltestosterone supplementation and risk of breast cancer in postmenopausal women. / Kabat, Geoffrey C.; Kamensky, Victor; Heo, Moonseong; Bea, Jennifer W; Hou, Lifang; Lane, Dorothy S.; Liu, Simin; Qi, Lihong; Simon, Michael S.; Wactawski-Wende, Jean; Rohan, Thomas E.

In: Maturitas, Vol. 79, No. 1, 2014, p. 70-76.

Research output: Contribution to journalArticle

Kabat, GC, Kamensky, V, Heo, M, Bea, JW, Hou, L, Lane, DS, Liu, S, Qi, L, Simon, MS, Wactawski-Wende, J & Rohan, TE 2014, 'Combined conjugated esterified estrogen plus methyltestosterone supplementation and risk of breast cancer in postmenopausal women', Maturitas, vol. 79, no. 1, pp. 70-76. https://doi.org/10.1016/j.maturitas.2014.06.006
Kabat, Geoffrey C. ; Kamensky, Victor ; Heo, Moonseong ; Bea, Jennifer W ; Hou, Lifang ; Lane, Dorothy S. ; Liu, Simin ; Qi, Lihong ; Simon, Michael S. ; Wactawski-Wende, Jean ; Rohan, Thomas E. / Combined conjugated esterified estrogen plus methyltestosterone supplementation and risk of breast cancer in postmenopausal women. In: Maturitas. 2014 ; Vol. 79, No. 1. pp. 70-76.
@article{d550b42579e8434d8272f06d9203fbad,
title = "Combined conjugated esterified estrogen plus methyltestosterone supplementation and risk of breast cancer in postmenopausal women",
abstract = "Objectives Testosterone supplementation is being prescribed increasingly to treat symptoms of hormone deficiency in pre- and postmenopausal women; however, studies of the association of testosterone therapy, alone or in combination with estrogen, with risk of breast cancer are limited. The current study assessed the association of combination conjugated esterified estrogen and methyltestosterone (CEE + MT) use and breast cancer risk in postmenopausal women in the Women's Health Initiative (WHI). Study design At Year 3 of follow-up, women in the WHI observational study (N = 71,964) provided information on CEE + MT use in the past two years, duration of use, and the brand name of the product. In addition, in each of years 4-8, women were asked whether they had used CEE + MT in the previous year. After 10 years of follow-up, 2832 incident breast cancer cases were identified. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95{\%} confidence intervals (95{\%} CI) for the association of CEE + MT use (irrespective of use of other hormones) and of exclusive CEE + MT use in relation to breast cancer risk. Results Neither CEE + MT use nor exclusive use of CEE + MT was associated with risk: multivariable-adjusted HR 1.06, 95{\%} CI 0.82-1.36 and HR 1.22, 95{\%} CI 0.78-1.92, respectively. Among women with a natural menopause, the HR for exclusive use was 1.32 (95{\%} CI 0.68-2.55). There was no indication of an association when repeated measures of CEE + MT use were included in a time-dependent covariates analysis. Conclusion The present study, the largest prospective study to date, did not show a significant association of CEE + MT supplementation and risk of breast cancer.",
keywords = "Androgens, Breast cancer, Conjugated esterified estrogen plus methyltestosterone supplementation, Postmenopausal women",
author = "Kabat, {Geoffrey C.} and Victor Kamensky and Moonseong Heo and Bea, {Jennifer W} and Lifang Hou and Lane, {Dorothy S.} and Simin Liu and Lihong Qi and Simon, {Michael S.} and Jean Wactawski-Wende and Rohan, {Thomas E.}",
year = "2014",
doi = "10.1016/j.maturitas.2014.06.006",
language = "English (US)",
volume = "79",
pages = "70--76",
journal = "Maturitas",
issn = "0378-5122",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Combined conjugated esterified estrogen plus methyltestosterone supplementation and risk of breast cancer in postmenopausal women

AU - Kabat, Geoffrey C.

AU - Kamensky, Victor

AU - Heo, Moonseong

AU - Bea, Jennifer W

AU - Hou, Lifang

AU - Lane, Dorothy S.

AU - Liu, Simin

AU - Qi, Lihong

AU - Simon, Michael S.

AU - Wactawski-Wende, Jean

AU - Rohan, Thomas E.

PY - 2014

Y1 - 2014

N2 - Objectives Testosterone supplementation is being prescribed increasingly to treat symptoms of hormone deficiency in pre- and postmenopausal women; however, studies of the association of testosterone therapy, alone or in combination with estrogen, with risk of breast cancer are limited. The current study assessed the association of combination conjugated esterified estrogen and methyltestosterone (CEE + MT) use and breast cancer risk in postmenopausal women in the Women's Health Initiative (WHI). Study design At Year 3 of follow-up, women in the WHI observational study (N = 71,964) provided information on CEE + MT use in the past two years, duration of use, and the brand name of the product. In addition, in each of years 4-8, women were asked whether they had used CEE + MT in the previous year. After 10 years of follow-up, 2832 incident breast cancer cases were identified. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI) for the association of CEE + MT use (irrespective of use of other hormones) and of exclusive CEE + MT use in relation to breast cancer risk. Results Neither CEE + MT use nor exclusive use of CEE + MT was associated with risk: multivariable-adjusted HR 1.06, 95% CI 0.82-1.36 and HR 1.22, 95% CI 0.78-1.92, respectively. Among women with a natural menopause, the HR for exclusive use was 1.32 (95% CI 0.68-2.55). There was no indication of an association when repeated measures of CEE + MT use were included in a time-dependent covariates analysis. Conclusion The present study, the largest prospective study to date, did not show a significant association of CEE + MT supplementation and risk of breast cancer.

AB - Objectives Testosterone supplementation is being prescribed increasingly to treat symptoms of hormone deficiency in pre- and postmenopausal women; however, studies of the association of testosterone therapy, alone or in combination with estrogen, with risk of breast cancer are limited. The current study assessed the association of combination conjugated esterified estrogen and methyltestosterone (CEE + MT) use and breast cancer risk in postmenopausal women in the Women's Health Initiative (WHI). Study design At Year 3 of follow-up, women in the WHI observational study (N = 71,964) provided information on CEE + MT use in the past two years, duration of use, and the brand name of the product. In addition, in each of years 4-8, women were asked whether they had used CEE + MT in the previous year. After 10 years of follow-up, 2832 incident breast cancer cases were identified. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (95% CI) for the association of CEE + MT use (irrespective of use of other hormones) and of exclusive CEE + MT use in relation to breast cancer risk. Results Neither CEE + MT use nor exclusive use of CEE + MT was associated with risk: multivariable-adjusted HR 1.06, 95% CI 0.82-1.36 and HR 1.22, 95% CI 0.78-1.92, respectively. Among women with a natural menopause, the HR for exclusive use was 1.32 (95% CI 0.68-2.55). There was no indication of an association when repeated measures of CEE + MT use were included in a time-dependent covariates analysis. Conclusion The present study, the largest prospective study to date, did not show a significant association of CEE + MT supplementation and risk of breast cancer.

KW - Androgens

KW - Breast cancer

KW - Conjugated esterified estrogen plus methyltestosterone supplementation

KW - Postmenopausal women

UR - http://www.scopus.com/inward/record.url?scp=84928060012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928060012&partnerID=8YFLogxK

U2 - 10.1016/j.maturitas.2014.06.006

DO - 10.1016/j.maturitas.2014.06.006

M3 - Article

VL - 79

SP - 70

EP - 76

JO - Maturitas

JF - Maturitas

SN - 0378-5122

IS - 1

ER -